Medytox

Based on integrity and open communication, Medytox is building excellent capacity and system to meet the global standard with commitment and courage. Furthermore, we are endeavoring to reach $1 billion in sales, $10 billion in market value and to become one of the world’s top 20 biopharmaceutical companies.

Medytox, a global biopharmaceutical company, is at the forefront of efforts to build a better future with ceaseless R&D.

Since the launch of botulinum toxin type A Meditoxin® in 2006 (trade name: Neuronox®, Siax®, Botulift®, Cunox®, Acebloc®, and Meditoxin®), Medytox has shown dramatic growth. Medytox reached nearly 40% of the market share in Korea since 2009 and is expected to increase even further with various indications being included.

The global botulinum toxin market continues to grow and is expected to further expand to not only the medical aesthetics market but also the therapeutic market. Medytox is stunning in the world with a high market share in the global botulinum market.

With the goal of penetrating the US and Europe, we plan to exceed 10% of the market share in the global market along with the launch of the currently developing new type botulinum toxin products.

In the future, Medytox will grow as the leader of the biopharmaceutical industry by challenging ourselves with passion for the global market.